Jazz Pharmaceuticals Announces Third Quarter 2021 Financial Results And Raises Full Year Earnings Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/7/2026
- S&P 500, Nasdaq close sharply higher as Broadcom rallies
- Oil prices settle at pre-Iran war levels as crude output grows
- Broadcom stock pops 4% as Apple silicon deal gets extended through 2031
- Buy the pullback in chip stocks, JPM's Matejka says
- Memory stocks rebound as analysts flag a buying opportunity
- Rivian Automotive (RIVN) files for 75M share offering
- Rivian offers Q2 2026 revenue outlook, cash position grows
- Nokia OYJ (NOKIA:FH) (NOK) PT Raised to EUR14 at Kepler Cheuvreux
- Meta capex to surge in 2027, neocloud fears ’erroneous’ - SemiAnalysis
- Coursera plans layoffs after Udemy merger, estimates $8M-$11M in costs
Jazz Pharmaceuticals (JAZZ) PT Lowered to $202 at BMO Capital
November 10, 2021 6:33 AM ESTBMO Capital analyst Gary Nachman lowered the price target on Jazz Pharmaceuticals (NASDAQ: JAZZ) to $202.00 (from $205.00) while maintaining an Outperform rating.
The analyst commented, "3Q results beat with meaningfully lower opex driving significant EPS upside. Individual products were somewhat mixed, but we're seeing... More
Jazz Pharmaceuticals (JAZZ) Tops Q3 EPS by 89c
November 9, 2021 4:23 PM ESTJazz Pharmaceuticals (NASDAQ: JAZZ) reported Q3 EPS of $4.20, $0.89 better than the analyst estimate of $3.31. Revenue for the quarter came in at $838.1 million versus the consensus estimate of $832.52 million.
For earnings history and earnings-related data on Jazz Pharmaceuticals (JAZZ) click here.
... More